Capital Research Global Investors 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 12:22 pm Sale |
2022-02-14 | 13G | Allogene Therapeutics, Inc. ALLO |
Capital Research Global Investors | 0 0.000% |
-12,640,338 (Position Closed) |
Filing |
| 2021-02-16 3:46 pm Purchase |
2021-02-16 | 13G | Allogene Therapeutics, Inc. ALLO |
Capital Research Global Investors | 12,640,338 9.000% |
6,097,660 (+93.20%) |
Filing |